DILAUDID

This brand name is authorized in United States. It is also authorized in Australia, Canada.

Active ingredients

The drug DILAUDID contains one active pharmaceutical ingredient (API):

1	Hydromorphone UNII L960UP2KRW - HYDROMORPHONE HYDROCHLORIDE
	Hydromorphone is an agonist of mu receptors. The pharmacological actions of hydromorphone and morphine do not differ significantly. Hydromorphone and related opioids produce their major effects on the central nervous system and bowel. Hydromorphone is indicated for the relief of severe pain in cancer.
	Read more about Hydromorphone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DILAUDID Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N02AA03	Hydromorphone	N Nervous system → N02 Analgesics → N02A Opioids → N02AA Natural opium alkaloids
Discover more medicines within N02AA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11467M, 11479E, 12010D, 12016K, 12032G, 12045Y, 12046B, 12047C, 12484C, 12485D, 12493M, 12497R, 12515Q, 12531M, 5115F, 5116G, 5117H, 8420E, 8421F, 8541M, 8542N, 8543P
CA	Health Products and Food Branch	00125083, 00125121, 00705438, 00786543
US	FDA, National Drug Code	42858-122, 42858-234, 42858-338, 42858-416, 76045-009, 76045-010, 76045-121